The impact of escalating regulatory requirements on the conduct of clinical research

Cytotherapy

Volumn 5, Issue 4, 2003, Pages 309-313

  Gordon, B G ^a   Kessinger, Anne ^a   Mann, S L ^b   Prentice, E D ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Clinical research; Regulatory issues

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; INFORMED CONSENT; MEDICAL AUDIT; MEDICAL ETHICS; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROTECTION; QUALITY CONTROL; REVIEW; RISK BENEFIT ANALYSIS; VOLUNTEER;

EID: 0142063069     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310002225     Document Type: Review

References (12)

1. Belmont report: Ethical principles and guidelines for the protection of human subjects of research. http://ohrp.osophs.dhhs.gov/humansubjects/guidance/belmont.htm visited 25th May 2003.
2. World Medical Association Declaration of Helsinki http://www.cirp.org/library/ethics/helsinki visited 25th May 2003.
3. Gelsinger, Paul. Jesse's intent. In; Amdur RJ, Bankert EA, editors. Institutional Review Board: Management and Function Sudbury, MA: Jones and Bartlett, 2001: xv-xxiv.
4. Brody B, Anderson C, McCrary SV et al. Expanding disclosure of conflict of interests: The views of the stakeholders. IRB. Ethics Hum Res 2003;25:1-8.
5. Emanuel EJ, Steiner D. Institutional conflict of interest. N Engl J Med 1995;332:262-7.
6. Angell M. Is academic medicine for sale? N Engl J Med 2000;342:1516-8.
7. Goldner JA. Dealing with conflicts of interest in biomedical research: IRB oversight as the next best solution to the abolitionist approach. J Law Med Ethics 2000;28:379-404.
8. Prentice E, Epperson K, Kratochvil C, Gordon B. IRB review of adverse events. In: Amdur RJ, Bankert EA, editors. Institutional Review Board: Management and Function Sudbury, MA: Jones and Bartlett, 2001.
9. Prentice ED, Gordon BG. IRB review of adverse events in investigational drug studies. IRB: Rev Human Subj Res 1997;19:1.
10. Department of Health and Human Services, Office of the Inspector General. Institutional Review Boards: A Time for Reform. (OEI-01-97-00193) http://oig.hhs.gov/oei/reports/oei-01-97-00193.pdf visited 25th May 2003.
11. United States General Accounting Office. Scientific research: Continued vigilance critical to protecting human subjects (GAO/HEHS-96-72) http://www.gao.gov/archive/1996/he96072.pdf visited 25th May 2003.
12. Bankert, E, Amdur, R. The IRB is not a data and safety monitoring board. IRB: Rev Hum Subj Res 2000;22:9-11.